<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02593357</url>
  </required_header>
  <id_info>
    <org_study_id>2012/55</org_study_id>
    <nct_id>NCT02593357</nct_id>
  </id_info>
  <brief_title>Peripheral Endothelial Function in COPD Patients</brief_title>
  <acronym>endothBPCO</acronym>
  <official_title>Assessment of a Peripheral Endothelial Dysfunction in COPD (Chronic Obstructive Pulmonary Disease)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hopital Foch</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hopital Foch</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to assess the peripheral endothelial function in adult COPD (chronic
      obstructive pulmonary disease) patients and the relationship between the peripheral
      endothelial function and the pulmonary function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary criteria is the peripheral endothelial function that will be assessed by the
      measure of flow-mediated dilation (reactive hyperemia-peripheral artery tone index). The
      pulmonary function will be assessed by the measures of the FEV1 (forced expiratory volume in
      one second), the forced vital capacity (FVC) and the expiratory flow between 25% and 75%
      (FEF25-75%). The relationship between these parameters of the pulmonary function and the
      peripheral endothelial function will be analyzed. In addition, a relationship between
      peripheral endothelial function and the severity of COPD (classification according to GOLD
      (Global Initiative for Chronic Obstructive Lung Disease) 2010 and GOLD 2011 and the COPD
      assessment test, the cardiovascular risk factors (SCORE INdex) and the smoker status will be
      also assessed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">November 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>measure of reactive hyperemia-peripheral artery tone index</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>measure of Forced expiratory flow in one second</measure>
    <time_frame>day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of forced vital capacity</measure>
    <time_frame>day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of expiratory flow between 25% and 75% (FEF25-75%).</measure>
    <time_frame>day 1</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>COPD patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>measure of endothelial function with EndoPAT® in COPD patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>COPD patients</intervention_name>
    <description>measure of peripheral endothelial function by the reactive hyperemia-peripheral artery tone index with a specific device (EndoPAT®)</description>
    <arm_group_label>COPD patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  COPD : FEV1/FVC &lt; 70%

          -  Smokers or ex-smokers ( ≥ 10 pack-years)

          -  No COPD exacerbation in the last three months

          -  No history of asthma and no respiratory allergy

        Exclusion Criteria:

          -  Pregnant or nursing women

          -  Treatment with pulmonary vasodilators

          -  Patients with a significant acute disease. A significant disease is defined as a
             disease which, in the opinion of the investigator, may influence the results of the
             trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Philippe Devillier, MD PhD</last_name>
    <phone>33 1 46 25 27 91</phone>
    <email>p.devillier@hopital-foch.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hélène Neveu, MD</last_name>
    <email>h.neveu@hopital-foch.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Saint-Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Foch</name>
      <address>
        <city>Suresnes</city>
        <zip>92150</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hélène Neveu, MD</last_name>
      <email>h.neveu@hopital-foch.org</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 16, 2015</study_first_submitted>
  <study_first_submitted_qc>October 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2015</study_first_posted>
  <last_update_submitted>September 19, 2016</last_update_submitted>
  <last_update_submitted_qc>September 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>endothelial function</keyword>
  <keyword>COPD</keyword>
  <keyword>pulmonary function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

